Posted by Michael Wonder on 01 Oct 2025
Novo Nordisk resubmits Awiqli to the FDA with potential to be the first once weekly basal insulin treatment for adults with type 2 diabetes
29 September 2025 - Awiqli (insulin icodec) injection, if approved, has the potential to be the first once weekly basal insulin treatment available in the US for adult type 2 diabetes.
Novo Nordisk today announced the resubmission of its biologics license application to the US FDA for Awiqli (insulin icodec) injection, a once weekly basal insulin treatment for adults living with type 2 diabetes.
